AMIGOs: Summary
Glucose control improved in combination with metformin and/or sulfonylurea
Improved glycemic control was accompanied by weight loss
Generally well tolerated
- Most common adverse events were gastrointestinal in nature, generally mild to moderate, and occurred more frequently at initiation
- Hypoglycemia was generally mild to moderate and most common in SFU-treated patients
Form basis of NDA submission in mid-2004